<DOC>
	<DOCNO>NCT00003242</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness chemotherapy bryostatin 1 plus paclitaxel cisplatin treat patient advance solid tumor .</brief_summary>
	<brief_title>Bryostatin 1 Plus Paclitaxel Cisplatin Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intravenous bryostatin 1 administer combination fix dose paclitaxel cisplatin patient advance solid tumor . II . Investigate clinical pharmacokinetics intravenous paclitaxel administer combination bryostatin 1 patient . III . Obtain preliminary data therapeutic activity therapy patient evaluate surrogate marker activity . OUTLINE : This open label , dose escalation study . Patients receive paclitaxel IV 1 hour day 1 . On day 2 , patient receive bryostatin 1 IV 1 hour immediately follow cisplatin IV day 2 . Treatment repeat weekly 3 consecutive week follow one week rest least 2 course . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient enter escalate dose level bryostatin 1 paclitaxel . If 2 6 patient experience dose limit toxicity ( DLT ) give dose level , maximum tolerate dose ( MTD ) declare precede dose level . Once MTD paclitaxel bryostatin 1 establish , escalation weekly cisplatin add . Additional patient cohort receive two escalate dos paclitaxel cisplatin fix bryostatin 1 dose level , absence DLT . Patients low bryostatin 1 dose may escalate high bryostatin 1 dose , high dose proven safe another cohort patient . PROJECTED ACCRUAL : An anticipated 3 60 patient accrue study within 1-14 month .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor Must refractory standard therapy standard therapy exist No CNS metastases CNS primary malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No history cardiac arrhythmia No congestive heart failure No myocardial infarction last 6 month Neurologic : No grade 3 great neurotoxicity Other : HIV negative No serious uncontrolled infection Not pregnant Adequate contraception require fertile patient study 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : At least 6 week since prior nitrosoureas mitomycin At least 4 week since prior chemotherapy Must recover prior chemotherapy Endocrine therapy : Must recover prior endocrine therapy Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>